BRPI0415212A - método de diagnose da doença de alzheimer ou estágio inicial ou predisposição para a mesma e respectivo kit de diagnose - Google Patents

método de diagnose da doença de alzheimer ou estágio inicial ou predisposição para a mesma e respectivo kit de diagnose

Info

Publication number
BRPI0415212A
BRPI0415212A BRPI0415212-3A BRPI0415212A BRPI0415212A BR PI0415212 A BRPI0415212 A BR PI0415212A BR PI0415212 A BRPI0415212 A BR PI0415212A BR PI0415212 A BRPI0415212 A BR PI0415212A
Authority
BR
Brazil
Prior art keywords
predisposition
alzheimer
disease
early stage
diagnosis method
Prior art date
Application number
BRPI0415212-3A
Other languages
English (en)
Inventor
Thomas Arendt
Jens Stieler
Original Assignee
Universitot Leizig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitot Leizig filed Critical Universitot Leizig
Publication of BRPI0415212A publication Critical patent/BRPI0415212A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

"MéTODO DE DIAGNOSE DA DOENçA DE ALZHEIMER OU ESTáGIO INICIAL OU PREDISPOSIçãO PARA A MESMA E RESPECTIVO KIT DE DIAGNOSE". A presente invenção relaciona-se com método de diagnose da doença de Alzheimer ou estágio inicial ou predisposição para esta doença. O referido método é baseado na quantificação de marcador de superfície mitogenicamente expressível, em particular CD69, e células perifericamente acessíveis, por exemplo, células da pele ou linfócitos, (a) antes e (b) depois de estimulação mitogênica. Um índice especial de estimulação a:b é uma indicação da doença de Alzheimer ou estágio inicial ou predisposição para esta doença. A invenção também se relaciona com kits que são adequados para executar o método de diagnose inventivo.
BRPI0415212-3A 2003-10-22 2004-09-29 método de diagnose da doença de alzheimer ou estágio inicial ou predisposição para a mesma e respectivo kit de diagnose BRPI0415212A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10349162A DE10349162A1 (de) 2003-10-22 2003-10-22 Schnelltest zur Diagnose der Alzheimerschen Erkrankung
PCT/EP2004/010889 WO2005050219A1 (de) 2003-10-22 2004-09-29 Schnelltest zur diagnose der alzheimerschen erkrankung

Publications (1)

Publication Number Publication Date
BRPI0415212A true BRPI0415212A (pt) 2006-12-05

Family

ID=34529710

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415212-3A BRPI0415212A (pt) 2003-10-22 2004-09-29 método de diagnose da doença de alzheimer ou estágio inicial ou predisposição para a mesma e respectivo kit de diagnose

Country Status (15)

Country Link
US (2) US20070218497A1 (pt)
EP (1) EP1685408A1 (pt)
JP (1) JP2007509331A (pt)
KR (1) KR101138343B1 (pt)
CN (1) CN1871519A (pt)
AU (1) AU2004290789B2 (pt)
BR (1) BRPI0415212A (pt)
CA (1) CA2540841A1 (pt)
DE (1) DE10349162A1 (pt)
IL (1) IL175004A0 (pt)
NO (1) NO335704B1 (pt)
RS (2) RS20060255A (pt)
RU (1) RU2426130C2 (pt)
WO (1) WO2005050219A1 (pt)
ZA (1) ZA200603178B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1876449A1 (en) * 2006-07-07 2008-01-09 Universität Leipzig Cell cycle-based blood test to diagnose Alzheimer's disease
AU2010207640B2 (en) * 2009-01-20 2016-09-08 Cambridge Enterprise Limited Methods for predicting autoimmune disease risk
GB201212084D0 (en) * 2012-07-06 2012-08-22 Randox Lab Ltd Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment
WO2014205406A1 (en) * 2013-06-20 2014-12-24 Amarantus Bioscience Holdings, Inc. Methods, systems, and composition related to neural disorders
CN106885909B (zh) * 2017-01-19 2018-11-20 上海市东方医院 一种用于早期诊断阿尔茨海默病的试剂盒
CA3055754A1 (en) * 2017-03-06 2018-09-13 Talaris Therapeutics, Inc. Methods and compositions for determining the potency of a therapeutic cellular composition
MX2022000444A (es) * 2019-07-10 2022-02-10 Todos Medical Ltd Un biomarcador para la enfermedad de alzheimer utilizando muestras de sangre de sujetos con diagnostico clinico de la enfermedad de alzheimer.
CN117210549B (zh) * 2023-08-29 2025-03-07 遵义市第一人民医院(遵义医学院第三附属医院) 检测人atp5d、cd69和cxcr4基因的物质及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19936035C2 (de) * 1999-07-30 2002-11-21 Univ Leipzig Lymphozytenproliferationstestkit
US20020081635A1 (en) * 2000-05-11 2002-06-27 Thomas Terry E. Novel antibody compositions for preparing enriched T cell preparations

Also Published As

Publication number Publication date
JP2007509331A (ja) 2007-04-12
RS20060255A (sr) 2008-09-29
CN1871519A (zh) 2006-11-29
US20150079609A1 (en) 2015-03-19
DE10349162A1 (de) 2005-06-02
US20070218497A1 (en) 2007-09-20
NO20061758L (no) 2006-07-06
WO2005050219A1 (de) 2005-06-02
CA2540841A1 (en) 2005-06-02
KR101138343B1 (ko) 2012-04-26
AU2004290789B2 (en) 2010-01-21
RS52875B (sr) 2013-12-31
RU2426130C2 (ru) 2011-08-10
ZA200603178B (en) 2007-07-25
AU2004290789A1 (en) 2005-06-02
IL175004A0 (en) 2006-08-20
NO335704B1 (no) 2015-01-26
KR20060100423A (ko) 2006-09-20
RU2006112203A (ru) 2007-11-27
EP1685408A1 (de) 2006-08-02

Similar Documents

Publication Publication Date Title
BR0301719A (pt) Processo para diagnosticar enfarte do miocárdio e/ou estratificação de risco da sìndrome aguda das coronárias, conjunto de reagentes para realizar esse diagnóstico e utilização do mesmo
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
ATE232620T1 (de) Reflexalgorithmus zur frühen und kostengünstigen diagnose von myokardischen infarkten geeignet für automatisierte diagnostische plattformen
BRPI0412725A (pt) marcadores para detecção de cáncer gástrico
ES2160716T3 (es) Procedimiento para estabilizar la respuesta de un biosensor.
BRPI0413576A (pt) sistema e método para facilitar a seleção centralizada de candidatos e a monitoração da participação de pessoas em estudos de testes clìnicos
BRPI0415212A (pt) método de diagnose da doença de alzheimer ou estágio inicial ou predisposição para a mesma e respectivo kit de diagnose
WO2022104136A3 (en) Methods and compositions for tauopathy diagnosis and treatment
ES2531368T3 (es) Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno
BR112012005670A2 (pt) ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
BR9607854A (pt) Processos para a medição da taxa de degradação de uma proteína do corpo e para obtenção de informação referente à degradação de proteína em um paciente utilização de um isômero sintético de um peptídeo e de um anticorpo anticorpo capa de células análogo de peptídeo sintético e kit de análise para utilização em um processo de análise
BR0014150A (pt) Diagnósticos e terapêuticos para osteoporose
BRPI0511127A (pt) prouroguanilina e análogos sintéticos ou produtos da clivagem proteolìtica dela derivados, como agentes terapêuticos e de diagnósticos para doenças que envolvem a homeostasia de sal e/ou de lìquidos
BR0211697A (pt) Marcador de câncer e usos deste na diagnose de câncer
BR0109915A (pt) Teste de diagnóstico para doença de alzheimer
Turner-Stokes Poststroke depression: getting the full picture.
Carol et al. The prediction of state board examination scores of graduates of an associate degree program
BR9808373A (pt) Processo rápido para o diagnóstico de câncer
BRPI0512336A (pt) métodos de diagnósticos para osteoporose
BR0111975A (pt) Fator, composição, veìculo, ligando, kits de diagnósticos, processos para detectar uma prpsc em uma amostra, e para remover prpsc de material biológico, método para diagnosticar encefalopatias espongiformes humanas transmissìveis e encefalopatias de prìons de animais, e, uso de um fator
BRPI0415562A (pt) reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma
EP1767652A4 (en) GENMARKER AND ITS USE
Paolo et al. Influence of perceptual organization and naming abilities on the Hooper Visual Organization Test: A replication and extension
BR0209681A (pt) Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente
BR0015285A (pt) Método para diagnosticar uma condição de um tecido alvo, método para diagnosticar tecidos displásticos, e sistema para determinar uma condição de um tecido biológico alvo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL